“A few polymerase inhibitors are in development: two in clinical trials. But there is no data
yet and speculation scuttle-butt in the halls here was that these drugs may have limited antiviral activity.” (
AASLD Conference: New Therapeutic Strategies for Hepatitis C Chicago, June 15-16, 2001 Reported by Jules Levin).
Isis Pharmaceuticals of Carlsbad, CA, is in Phase II trials with a drug that tries to interfere with a different part of hepatitis C.